XML 53 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1

Revenue Recognition and Accounts Receivable Segment revenue by major payor (Tables)

12 Months Ended

Dec. 31, 2023

Disaggregation of Revenue [Abstract]

Disaggregation of Revenue

The Company's revenues by segment and primary payor source were as follows:

			Year ended December 31, 2023
			U.S. dialysis						Other - Ancillary services						Consolidated
Patient service revenues:
Medicare and Medicare Advantage			$	6,100,183					$						$	6,100,183
Medicaid and Managed Medicaid			833,744												833,744
Other government			354,304						500,137						854,441
Commercial			3,623,516						251,279						3,874,795
Other revenues:
Medicare and Medicare Advantage									460,991						460,991
Medicaid and Managed Medicaid									1,733						1,733
Commercial									32,329						32,329
Other(1)			25,251						52,754						78,005
Eliminations of intersegment revenues			(88,222)						(7,852)						(96,074)
Total			$	10,848,776					$	1,291,371					$	12,140,147

    

(1)Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.

			Year ended December 31, 2022
			U.S. dialysis						Other - Ancillary services						Consolidated
Patient service revenues:
Medicare and Medicare Advantage			$	6,041,496					$						$	6,041,496
Medicaid and Managed Medicaid			759,579												759,579
Other government			336,991						464,921						801,912
Commercial			3,437,306						223,216						3,660,522
Other revenues:
Medicare and Medicare Advantage									345,340						345,340
Medicaid and Managed Medicaid									1,546						1,546
Commercial									22,211						22,211
Other(1)			24,437						44,092						68,529
Eliminations of intersegment revenues			(87,035)						(4,206)						(91,241)
Total			$	10,512,774					$	1,097,120					$	11,609,894

(1)Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.

			Year ended December 31, 2021
			U.S. dialysis						Other - Ancillary services						Consolidated
Patient service revenues:
Medicare and Medicare Advantage			$	6,133,235					$						$	6,133,235
Medicaid and Managed Medicaid			782,430												782,430
Other government			328,256						463,385						791,641
Commercial			3,397,697						199,024						3,596,721
Other revenues:
Medicare and Medicare Advantage									326,696						326,696
Medicaid and Managed Medicaid									1,321						1,321
Commercial									15,553						15,553
Other(1)			25,345						40,945						66,290
Eliminations of intersegment revenues			(90,796)						(4,294)						(95,090)
Total			$	10,576,167					$	1,042,630					$	11,618,797

(1)Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.

X

- References

No definition available.

+ Details

Name:	us-gaap_DisaggregationOfRevenueAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration